Jazz Pharmaceuticals (JAZZ) Other Non-Current Assets (2016 - 2025)
Jazz Pharmaceuticals has reported Other Non-Current Assets over the past 16 years, most recently at $7.6 million for Q4 2025.
- Quarterly Other Non-Current Assets fell 93.41% to $7.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.6 million through Dec 2025, down 93.41% year-over-year, with the annual reading at $7.6 million for FY2025, 93.41% down from the prior year.
- Other Non-Current Assets was $7.6 million for Q4 2025 at Jazz Pharmaceuticals, down from $8.0 million in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $121.3 million in Q2 2025 and troughed at $4.7 million in Q1 2021.
- The 5-year median for Other Non-Current Assets is $43.3 million (2021), against an average of $47.5 million.
- Biggest five-year swings in Other Non-Current Assets: soared 726.97% in 2024 and later crashed 93.41% in 2025.
- Tracing JAZZ's Other Non-Current Assets over 5 years: stood at $40.8 million in 2021, then plummeted by 77.33% to $9.3 million in 2022, then soared by 629.03% to $67.5 million in 2023, then soared by 69.69% to $114.5 million in 2024, then crashed by 93.41% to $7.6 million in 2025.
- According to Business Quant data, Other Non-Current Assets over the past three periods came in at $7.6 million, $8.0 million, and $121.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.